The United States Food and Drug Administration (USFDA) has approved Adempas (Riociguat) for the treatment of two forms of pulmonary hypertension in adults. The drug is to be marketed by Bayer Health-Care Pharmaceuticals Inc., Adempas is a soluble guanylate cyclase stimulator that aid arterial relaxation to augment blood flow and to reduce blood pressure. Adempas is indicated for adult patients with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical intervention and/or for patients who cannot undergo surgery. Adempas is also indicated for pulmonary arterial hypertension (PAH) patients with inherited and/or iatrogenic etiology or linked with connective tissue disorders. Adempas is indicated for such patients to improve the exercise ability and to delay the progression of clinical symptoms. According to Dr. Norman Stock-bridge, Director, Division of cardiovascular and renal drug products, Center for drug evaluation and research, USFDA, Adempas is the first approved drug that belongs to soluble guanylate cyclase class of drugs to treat PAH.